Cerulean Pharma Inc. (Nasdaq: CERU) announced top-line results from the Company’s Phase 2, randomized, multi-center clinical trial of its lead ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE